SLC12A2 and interstitial lung disease: Under similar experimental conditions (DIV14–DIV19), bath application of a concentration of bumetanide (200 μm) that blocks both NKCC1 and KCC2 cotransporters significantly reduced the mean frequency of spontaneous ILDs from 12.67 ± 5.6 to 6.8 ± 3.2 ILD/30 min.